We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Toremifene Appears Equivalent to Tamoxifen as Adjuvant Therapy for Breast Cancer: Interim Analysis

Feb 2, 1999
Volume: 
8
Issue: 
2
  • Breast Cancer

TAMPERE, Finland—Adjuvant treatment with the nonsteroidal
estrogen inhibitor toremifene (Fareston) proved equivalent to
tamoxifen (Nolvadex) for prevention of breast cancer recurrence but
was associated with fewer embolic events, investigators in an ongoing
Finnish trial reported at the San Antonio Breast Cancer Symposium.

Over a mean follow-up of 2.7 years, patients treated with toremifene
had an 18.3% recurrence rate, compared with 21.6% for tamoxifen (P =
.26). Toremifene patients had a lower overall incidence of embolic
events and a significantly lower incidence of cerebrovascular events.

“At this point, we really don’t have a good explanation for
the difference in embolic events,” said Kaija Holli, MD, an
oncologist at Tampere University Hospital. “We have started an
additional trial to learn more about the effects of toremifene on the
clotting system.”

Dr. Holli reported findings on the first 900 patients enrolled in a
study that ultimately will accrue a total of 1,460 patients.

All the patients are postmenopausal and have histologically verified
invasive breast cancer with spread to the axillary lymph nodes. More
than 60% of the women are estrogen-receptor positive. Patients
undergo segmental mastectomy and axillary lymph node dissection.
Patients are randomized to receive 40 mg of toremifene daily or 20 mg
of tamoxifen daily. Treatment continues for 3 years.

At the interim follow-up, the two agents proved equivalent in their
ability to prevent breast cancer recurrence. Dr. Holli said that 84
of 459 evaluable toremifene patients have had recurrences (11
locoregional, 73 distant) vs 95 of 440 tamoxifen patients (7
locoregional, 88 distant).

Analysis of cardiovascular events showed a trend in favor of
toremifene-treated patients. Overall, 19 toremifene patients have had
events, resulting in an incidence of 4.1%, compared with a 6.4%
incidence in the tamoxifen group. The major difference related to
cerebrovascular events, which occurred in 0.4% of toremifene patients
and 2.5% of tamoxifen patients (P = .01).

“There were fewer cardiovascular events in the toremifene
patients,” Dr. Holli said. “We carefully recorded all
possible adverse events. There is something going on with respect to
these events, but we cannot say what the reason is. We found the
difference between toremifene and tamoxifen very interesting.”

The Finnish investigators have planned other comparative trials
involving toremifene and tamoxifen. The trials will incorporate
careful scrutiny of lipid levels, endometrial changes, bone density,
and ocular changes. Dr. Holli said results could be available within
a year.

Dual Action

“Tamoxifen has been shown to reduce recurrences and subsequent
mortality from breast cancer but also has emerged with a variety of
unexpected effects, some of which are adverse,” she commented.

Part of the effects have been explained by the dual antiestrogenic
and estrogenic action of tamoxifen, she said. “Toremifene has
similar antiestrogenic and estrogenic effects, but it has a lower
estrogenic-to-antiestrogenic ratio than tamoxifen, which might help
explain differences between the two drugs, including the differences
we observed in this study.”

Related Articles

  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
  • COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
  • POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.